Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TENX 
Tenax Therapeutics Inc (TENX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: TENX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.8
1 Year Target Price $18.8
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 6.48% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.79M USD | Price to earnings Ratio 2.07 | 1Y Target Price 18.8 |
Price to earnings Ratio 2.07 | 1Y Target Price 18.8 | ||
Volume (30-day avg) 4 | Beta 1.44 | 52 Weeks Range 3.25 - 7.89 | Updated Date 09/16/2025 |
52 Weeks Range 3.25 - 7.89 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.94 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -37.61% | Return on Equity (TTM) -56.12% |
Valuation
Trailing PE 2.07 | Forward PE 0.3 | Enterprise Value 18771662 | Price to Sales(TTM) - |
Enterprise Value 18771662 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 4562500 | Shares Floating 4506075 |
Shares Outstanding 4562500 | Shares Floating 4506075 | ||
Percent Insiders 0.21 | Percent Institutions 64.83 |
Upturn AI SWOT
Tenax Therapeutics Inc
Company Overview
History and Background
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with significant unmet medical needs. Founded as Oxygen Biotherapeutics in 2004, it has gone through several transformations focusing on different products and ultimately settling on cardiovascular and pulmonary therapeutics.
Core Business Areas
- Cardiovascular Therapeutics: Focuses on developing and commercializing therapies for cardiovascular conditions, particularly those with limited treatment options.
- Pulmonary Therapeutics: Focuses on developing and commercializing therapies for pulmonary conditions, particularly those with limited treatment options.
Leadership and Structure
Tenax Therapeutics has a board of directors and an executive management team. The CEO leads the company's strategic direction and operational execution. The structure consists of research & development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Imatinib (TNK-701): Imatinib is being developed for the treatment of Pulmonary Arterial Hypertension (PAH). It is currently in clinical trials. Market share data is not currently available as the product is not yet approved. Competitors include companies offering approved PAH treatments like Actelion (acquired by Johnson & Johnson - JNJ), United Therapeutics (UTHR), and Bayer (BAYRY).
Market Dynamics
Industry Overview
The pharmaceutical industry, especially in cardiovascular and pulmonary diseases, is characterized by high regulatory hurdles, intense competition, and significant R&D investment. The market for PAH is substantial, with unmet needs for more effective and convenient therapies.
Positioning
Tenax Therapeutics is a small-cap company focusing on niche cardiovascular and pulmonary markets. Its competitive advantage depends on successful clinical trials and regulatory approval of its lead product candidate, Imatinib.
Total Addressable Market (TAM)
The PAH market is estimated to be several billion USD annually. Tenax Therapeutics' positioning depends on capturing a portion of this market through successful development and commercialization of Imatinib.
Upturn SWOT Analysis
Strengths
- Targeting unmet needs in cardiovascular and pulmonary diseases
- Focus on specific niche markets (e.g., PAH)
- Potential for orphan drug designation and market exclusivity
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- High risk of failure in drug development
- Relatively small company size
Opportunities
- Positive clinical trial results could lead to significant market value increase
- Partnerships with larger pharmaceutical companies
- Expansion into other cardiovascular and pulmonary indications
- Acquisition by a larger pharmaceutical company
Threats
- Failure in clinical trials
- Regulatory hurdles and delays
- Competition from existing therapies and new entrants
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- JNJ
- UTHR
- BAYRY
Competitive Landscape
Tenax Therapeutics faces intense competition from established pharmaceutical companies with approved PAH therapies. Its success depends on demonstrating superior efficacy or safety compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its development stage.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approval, and commercialization of Imatinib. Analyst estimates are highly speculative.
Recent Initiatives: Focus on advancing the clinical development of Imatinib (TNK-701) for PAH.
Summary
Tenax Therapeutics is a high-risk, high-reward development-stage pharmaceutical company. Its success hinges on the clinical development and regulatory approval of its lead product candidate, Imatinib. While it targets unmet needs in cardiovascular and pulmonary diseases, it faces significant competition and financial constraints. Investors should be aware of the speculative nature of the stock and the potential for volatility.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company website
- Third-party financial data providers
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on available data and analyst estimates, which are subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tenax Therapeutics Inc
Exchange NASDAQ | Headquaters Chapel Hill, NC, United States | ||
IPO Launch date 1997-01-02 | CEO, President & Director Mr. Christopher T. Giordano | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.tenaxthera.com |
Full time employees 4 | Website https://www.tenaxthera.com | ||
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.